Roche FY24 Core Operating Profit Rises
Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...
EARNINGS FORECAST: Roche's core earnings per share are expected to come in at 18.59 francs, according to the Visible Alpha consensus. For 2023, the company reported core EPS of 18.57 francs. As of ...
4d
Patients might not know about Roche Tissue Diagnostics, but the Arizona entity has been testing for cancer and helping devise ...
Roche has obtained U.S. government green lights allowing its point-of-care testing system to be used to screen for multiple ...
Effective February 10, 2025, Mamilli will assume global responsibility for the Informatics function for the Roche Group.
In this Made in Arizona, we're highlighting local artist Christopher Roach of Mesa. He uses art to showcase the beauty of ...
To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Roche has a big problem. With competition threatening some of its older and most lucrative biologic drugs, ...
Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics.Excluding COVID-19, Group sales increased by 9%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback